These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27534740)

  • 21. Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
    Wright D; Krajewska K; Bogdanova A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jun; 47(6):755-61. PubMed ID: 26726123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy.
    Crovetto F; Figueras F; Triunfo S; Crispi F; Rodriguez-Sureda V; Peguero A; Dominguez C; Gratacos E
    Fetal Diagn Ther; 2014; 35(4):258-66. PubMed ID: 24714555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenic profile and smoking in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
    Jääskeläinen T; Suomalainen-König S; Hämäläinen E; Pulkki K; Romppanen J; Heinonen S; Laivuori H;
    Ann Med; 2017 Nov; 49(7):593-602. PubMed ID: 28537456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a rapid and simple placental growth factor test in hypertensive disorders of pregnancy.
    Gullai N; Stenczer B; Molvarec A; Fügedi G; Veresh Z; Nagy B; Rigó J
    Hypertens Res; 2013 May; 36(5):457-62. PubMed ID: 23324863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
    Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort.
    Andersen LB; Dechend R; Jørgensen JS; Luef BM; Nielsen J; Barington T; Christesen HT
    Hypertens Pregnancy; 2016 Aug; 35(3):405-19. PubMed ID: 27159383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PP058. The additive effect of plasma levels of sFlt-1/PLGF ratio following the risk classification using both blood pressure levels and uterine artery blood flow impedance in the second trimester on the later occurrence of preeclampsia.
    Ohkuchi A; Hirashima C; Takahashi K; Matsubara S; Suzuki M
    Pregnancy Hypertens; 2012 Jul; 2(3):273. PubMed ID: 26105381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
    Dragan I; Georgiou T; Prodan N; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Jan; 49(1):73-77. PubMed ID: 27619203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
    Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can detection of late-onset PE at triage by sflt-1 or PlGF be improved by the use of additional biomarkers?
    Kaufmann I; Rusterholz C; Hösli I; Hahn S; Lapaire O
    Prenat Diagn; 2012 Dec; 32(13):1288-94. PubMed ID: 23108782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.
    Leaños-Miranda A; Campos-Galicia I; Berumen-Lechuga MG; Molina-Pérez CJ; García-Paleta Y; Isordia-Salas I; Ramírez-Valenzuela KL
    J Rheumatol; 2015 Jul; 42(7):1141-9. PubMed ID: 25979720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis.
    Álvarez-Fernández I; Prieto B; Rodríguez V; Ruano Y; Escudero AI; Álvarez FV
    Clin Chem Lab Med; 2014 Aug; 52(8):1159-68. PubMed ID: 24516004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.
    Lai J; Garcia-Tizon Larroca S; Peeva G; Poon LC; Wright D; Nicolaides KH
    Fetal Diagn Ther; 2014; 35(4):240-8. PubMed ID: 24853452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia.
    Di Lorenzo G; Ceccarello M; Cecotti V; Ronfani L; Monasta L; Vecchi Brumatti L; Montico M; D'Ottavio G
    Placenta; 2012 Jun; 33(6):495-501. PubMed ID: 22459245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
    Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
    Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia.
    Triunfo S; Crovetto F; Crispi F; Rodriguez-Sureda V; Dominguez C; Nadal A; Peguero A; Gratacos E; Figueras F
    Placenta; 2016 Jun; 42():44-50. PubMed ID: 27238713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
    Tan MY; Wright D; Koutoulas L; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):201-208. PubMed ID: 27671370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia.
    Rădulescu C; Bacârea A; Huțanu A; Gabor R; Dobreanu M
    Mediators Inflamm; 2016; 2016():3027363. PubMed ID: 27799724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center.
    Caillon H; Tardif C; Dumontet E; Winer N; Masson D
    Ann Lab Med; 2018 Mar; 38(2):95-101. PubMed ID: 29214752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.
    Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S
    Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.